WO2004049819A2 - Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein - Google Patents

Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein Download PDF

Info

Publication number
WO2004049819A2
WO2004049819A2 PCT/EP2003/013678 EP0313678W WO2004049819A2 WO 2004049819 A2 WO2004049819 A2 WO 2004049819A2 EP 0313678 W EP0313678 W EP 0313678W WO 2004049819 A2 WO2004049819 A2 WO 2004049819A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
solution
proteins
additive
fibrils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/013678
Other languages
French (fr)
Other versions
WO2004049819A3 (en
Inventor
Cecile Veerman
Leonard Martin Cornelia Sagis
Hendericus Gerardus Maria Baptist
Erik Van Der Linden
Suzanne Godelieve Bolder
William Kloek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Campina Melkune BV
Original Assignee
Campina Melkune BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Campina Melkune BV filed Critical Campina Melkune BV
Priority to JP2004556286A priority Critical patent/JP2006508160A/en
Priority to AU2003293761A priority patent/AU2003293761B2/en
Priority to US10/536,713 priority patent/US20060204454A1/en
Priority to NZ540406A priority patent/NZ540406A/en
Priority to EP03789127A priority patent/EP1565067A2/en
Publication of WO2004049819A2 publication Critical patent/WO2004049819A2/en
Publication of WO2004049819A3 publication Critical patent/WO2004049819A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A23J3/08—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A23J3/12—Animal proteins from blood
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/14—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/14—Vegetable proteins
    • A23J3/16—Vegetable proteins from soybean
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/14—Vegetable proteins
    • A23J3/18—Vegetable proteins from wheat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
    • A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
    • A23L13/424—Addition of non-meat animal protein material, e.g. blood, egg, dairy products, fish; Proteins from microorganisms, yeasts or fungi
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
    • A23L29/281—Proteins, e.g. gelatin or collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/01—Deodorant compositions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C2260/00—Particular aspects or types of dairy products
    • A23C2260/20—Dry foaming beverage creamer or whitener, e.g. gas injected or containing carbonation or foaming agents, for causing foaming when reconstituted
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to a method for improving the functional properties of a globular protein.
  • the invention further relates to the protein thus prepared, to the use thereof in various products as a protein additive, in particular as a thickening agent, foaming agent, viscosity enhancing agent and/or gelling agent and to the products comprising such additive.
  • Food and non-food additives are inter alia concerned with improving and maintaining product quality. They are for example used to provide texture, consistency and stability. For this they have functional properties such as foaming properties, gelling properties, emulsifying properties, thickening properties etc.
  • additives can be roughly divided into two groups, polysaccharides and proteins.
  • the first group having thickening properties are e.g. guar gum, xanthan gum, locust bean gum.
  • the second group are e.g. milk proteins.
  • milk proteins whey proteins are widely used as ingredients in food products for their ability to form gels.
  • ⁇ -Lactoglobulin is the major protein component of the whey protein from milk. It is a globular protein with a molar mass of 18.3 kDa and a diameter of about 2 nm.
  • the protein When the protein is dissolved in an aqueous solution above a certain critical concentration and heated above the denaturation temperature (about 78 °C) it forms a gel.
  • the globular structure unfolds at least partially and aggregates are formed.
  • the gel is formed by heat treatment if the concentration of the protein is above a critical value (C P ) , and an appropriate ionic strength is applied.
  • C P critical
  • Polysaccharides have the advantage that they are effective thickeners in food products, even in low amounts. However, the price of these hydrocolloids is normally high. Moreover, at elevated concentrations they may often give rise to taste defects. When used in dairy products like desserts, they are considered non-natural.
  • Proteins are normally less effective (on a w/w basis) in thickening compared to hydrocolloids. Thus, even though their price may be considerably lower than for hydrocolloids, the higher dose required abolishes the price advantage.
  • globular proteins form a gel when heated at neutral pH (around 7) .
  • the concentration needed to form the gel is relatively high, e.g. more than 5% (w/w) .
  • a gel thus obtained is irreversibly formed and is therefore not suitable for use as thickener in a range of products.
  • the gel would have to be dried and/or comminuted thus losing its thickening capacity.
  • whey proteins are thermally modified at neutral pH and low concentrations to avoid the undesired gel formation, the thickening capacity is very poor or not present at all.
  • proteins that have good functional properties, in particular thickening, gelling, foaming and emulsifying properties, and that are preferably highly effective at low concentrations.
  • the invention thus relates to a method comprising the steps of: a) providing a solution of one or more globular proteins, in which solution the protein is at least partially aggregated in fibrils; and b) performing one or more of the following steps in random order: i) adjusting the pH of the solution to about neutral; ii) increasing the salt concentration in the solution; ii) concentrating the solution; iii) changing the solvent quality of the solution.
  • Method step a) provides the fibrillar structures in the protein solution whereas method step b) triggers the protein such that it is ready to perform its function as a foaming, thickening, gelling or emulsifying agent upon addition thereof to the final product.
  • Providing a solution of the one or more globular proteins, in which solution the one or more proteins are at least partially aggregated in fibrils can be achieved in various ways.
  • the fibril-containing solution of the one or more globular proteins is provided by heating a solution of the protein above room temperature, preferably at a temperature between 50 and 100°C, at a pH between 0.5 and 4, preferably between 0.5 and 3.
  • the fibril-containing solution of the one or more globular proteins is provided by adding a denaturing agent to the solution.
  • the denaturing agent can be a hydrotropic or chaotropic agent and is for example selected from the group consisting of ureum, guanidinium chloride, alcohols, such as methanol, ethanol, propanol, butanol, trifluorethanol .
  • the treatment with the denaturing agent can be performed at a pH between 0.5 and 14, preferably between 3 and 11, more preferably between 5 and 9.
  • fibrils are formed having an unexpectedly high gelling and/or thickening and/or foaming and/or emulsifying capacity.
  • the fibrils are irreversibly formed and can be used at any desired pH or ionic strength.
  • Heating the solution in the first embodiment of step a) is preferably performed during at least 10 minutes, preferably at least 1 hour, more preferably at least 6 hours, most preferably at least 8 hours.
  • the pH of the treatment of the first embodiment of step a) is preferably below 2.8, preferably below 2.5, more preferably below 2.2.
  • Suitable acids for adjusting the pH to this value are food grade acids, such as hydrochloric acid, phosphoric acid, nitric acid or sulphuric acid.
  • the total heating time required to obtain the effect may be achieved by batch wise heating, continuous flow heating or a combination of subsequent heating steps, e.g. by means of circulating a solution through a heating system.
  • the solution is cooled before performing one or more of steps i) to iii) .
  • the solution It is preferred to cool the solution to a temperature between the denaturation temperature and 20°C, preferably between the denaturation temperature and 5°C.
  • Most food applications have a neutral, near neutral or slightly acidic pH.
  • the salt concentration is increased to a maximum of 0.2 M, preferably to 0.1 M.
  • the salt used for increasing the salt concentration is preferably the salt of a divalent ion, preferably calcium. It was found that by adding calcium the functional properties are further improved. According to a preferred embodiment step i) is performed prior to step ii) because pH adjustment in dilute systems is easier to carry out.
  • Changing the solvent quality of the solution can be performed by removing the denaturing agent, for example by dilution or dialysis.
  • the method further comprises addition of already formed fibrils to the solution of globular proteins prior to the heating step. It • was found that by means of this so-called seeding the heating time could be reduced. It was furthermore found that an even lower critical gelling concentration (Cp) could be obtained in samples that had been seeded as compared to samples that were not seeded. Seeds for addition to the solution can be prepared in the same way as the protein of the invention.
  • Cp critical gelling concentration
  • the method further comprises the step of drying the solution to obtain a dry product. It was found that upon reconstituting the protein additive of the invention from the powder obtained after drying the same or similar functional properties were obtained. It is practical when the drying comprises spray drying.
  • the dry product is preferably a powder. Alternatively granulates can be envisaged.
  • the globular protein is a protein that is substantially non-denatured and is capable of being thermally denatured at a temperature at or above the denaturation temperature of the protein or chemically denatured.
  • the method of the present invention can be performed with a wide variety of globular proteins, such as whey proteins, egg albumins, blood globulins, soy proteins, wheat proteins, in particular prolamines, potato proteins or pea proteins.
  • the globular protein is a whey protein isolate or a whey protein concentrate, preferably a whey protein concentrate enriched in (e.g. > 40%) ⁇ -lactoglobulin.
  • the globular protein is ⁇ -lactoglobulin.
  • the globular protein is the whey protein isolate powder (95% protein, w/w) that is commercially available under the name BiproTM and is composed of ⁇ 70% ⁇ -lactoglobuling, -18% -lactalbumin, -6% bovine serum albumin, and ⁇ 6% immunoglobulins .
  • the functional properties of this product after having been subjected to the method of the invention can be further improved by purifying the product prior to heating at low pH. Such purification comprises acidification to pH 4.75, centrifugation and use of the supernatant. This treatment results in loss of about 10% (aggregated) protein, mainly BSA.
  • the invention further relates to a protein additive for food and non-food applications based on a system of one or more proteins that are aggregated to form fibrils, characterized in that the protein additive has improved functional properties as compared to a similar protein additive based on a system of the same one or more proteins in the same concentration in which the proteins are not aggregated into fibrils.
  • Fibrils in this respect are preferably fibrils consisting of protein and having an aspect ratio of 5 or higher.
  • the aspect ratio is the ratio between length and width or length and height or length and diameter.
  • the length of the fibrils is preferably equal to or above 100A and equal to or below 1 mm, preferably below 100 ⁇ m. These fibrils can be made visible by means of a microscope.
  • the above described protein additive can be obtained by the method of the invention or by any other means that leads to the above described structural properties.
  • the protein additive of the invention can be used as a stabilizer of foams, dispersions and emulsions.
  • Foams are systems of a gas in a liquid.
  • Emulsions are liquids in liquids and dispersions are solids in liquids. Usually these systems cannot exist without the help of a stabilising agent that helps in maintaining the disperse phase uniformly distributed in the continuous phase.
  • the protein additive of the invention was found to be very suitable for this purpose.
  • the protein additive can be used in food stuffs, such as dairy products, for example (aerated) desserts, yogurts, flans, in bakery or confectionary applications, such as frappe, meringue, marshmallows, in cream liqueurs or in beverage foamers, such as cappuccino foamers.
  • Whey protein concentrate or whey protein isolate as the globular protein that constitutes the protein additive the product obtained can be an all milk product.
  • Whey protein concentrates normally comprise 25-90% (w/w) whey protein.
  • Whey protein isolates usually comprise > 90% whey protein.
  • the protein additive of the invention can also be used in meat products, e.g. comminuted meat products (Frankfurter sausages), hamburgers, luncheon meat, pate's, poultry, fish meat products or meat replacers on vegetable basis, to enhance the water-binding and/or texture of the product .
  • meat products e.g. comminuted meat products (Frankfurter sausages), hamburgers, luncheon meat, pate's, poultry, fish meat products or meat replacers on vegetable basis
  • Alternative applications of the protein additive of the invention can be found in non-food products such as paints, cosmetics, toothpastes, deodorants etc.
  • the invention further relates to products comprising the protein additive of the invention, such as food stuffs, in particular dairy products or meat products, but also nonfood products, e.g. paints, cosmetics, toothpastes, deodorants .
  • the invention relates to a protein composition
  • a protein composition comprising one or more particles having texturizing properties, wherein the protein molecules are aggregated into fibrils.
  • Texturizing properties comprise the ability to promote or modify the viscosity or gelling ability of a product containing the composition.
  • the fibrils have an aspect ratio, which is defined as the ratio between length and width or length and height or length and diameter, of 5 or higher.
  • the length of the fibrils is preferably equal to or above lOOA and equal to or below 1 mm, preferably below 100 ⁇ m.
  • the protein additive of the invention has improved functional properties. Functional properties comprise thickening capacity, gelling capacity, foaming capacity and emulsifying capacity and all have to do with the structure and texture of the product containing the additive.
  • the fact that the functional properties of the additive are improved means that the capacity to induce gelling, foaming, thickening or emulsification in the product containing the protein additive is improved as compared to the capacity to do so of the same protein in the same concentration but which is not subjected to the method of the invention.
  • Figure IA shows a TEM photograph of BiproTM treated according to the invention after different heating times.
  • Figure IB shows TEM photographs of ⁇ -lactoglobulin treated according to the invention after neutralization to different pHs .
  • Figure 2A shows meringue foam of treated and untreated BiproTM prior to drying.
  • Figure 2B shows meringue foam of treated and untreated BiproTM after drying.
  • FIG. 3 shows cappuccino foam prepared with treated and untreated BiproTM.
  • Figure 4 shows the overrun of a foam prepared with treated and untreated BiproTM.
  • Figure 5 shows the foam stability in time of a product prepared with treated and untreated BiproTM.
  • Figure 6 shows the drainage in time of a foam prepared with treated and untreated BiproTM.
  • Figure 7 shows the drainage in time of a foam prepared with treated and untreated BiproTM.
  • EXAMPLE 1 Preparation of ⁇ -lactoqlobulin gels according to the invention, and determination of critical gelling concentration ⁇ -Lactoglobulin ( ⁇ -lg) was obtained from Sigma (L- 0130) and is a mixture of the genetic variants A and B.
  • the protein was dissolved (3% w/w) in a HCl solution at pH 2.
  • HCl solvent To remove traces of calcium ions from the ⁇ -lg, and to obtain a protein solution with the same pH and ionic strength as the solvent, the protein was diluted repeatedly with HCl solvent and filtered through a 3K filter in an OmegacellTM membrane cell (Filtron) at 4°C and a maximum pressure of 3 bar.
  • the procedure was stopped, when the pH and conductivity of the diluted solution and the solvent were the same.
  • the ⁇ -lg solution was centrifuged at 22600g for 30 min. To remove any traces of undissolved protein, the supernatant was filtered through a protein filter (FP 030/2, 0.45 mm, Schleicher & Schuell).
  • a UV spectrophotometer was used to determine the ⁇ -lg concentration at a wavelength of 278 nm.
  • ⁇ -Lactoglobulin (w/w) as prepared above diluted to a concentration of 2% was heated at 80°C for 10 h in a water bath. After cooling, the pH was adjusted to pH 7 or 8 with 0.1 and 1 M NaOH.
  • ⁇ -lg gels Preparation of ⁇ -lg gels according to the conventional (neutral pH) gelation method, and determination of the critical gelling concentration ⁇ -Lactoglobulin ( ⁇ -lg) was obtained from Sigma (L- 0130) and is a mixture of the genetic variants A and B.
  • the protein was dissolved (3% w/w) in a HCl solution at pH 2.
  • HCl solvent To remove traces of calcium ions from the ⁇ -lg, and to obtain a protein solution with the same pH and ionic strength as the solvent, the protein was diluted repeatedly with HCl solvent and filtered through a 3K filter in an OmegacellTM membrane cell (Filtron) at 4°C and a maximum pressure of 3 bar. The procedure was stopped, when the pH and conductivity of the diluted solution and the solvent were the same.
  • the ⁇ -lg solution was centrifuged at 22600g for 30 min. To remove any traces of undissolved protein, the supernatant was filtered through a protein filter (FP 030/2, 0.45 mm, Schleicher & Schuell). A UV spectrophotometer was used to determine the ⁇ -lg concentration at a wavelength of 278 nm. 3% ⁇ -lg samples at pH 7 or 8 were heated at 80°C for
  • BiproTM a whey protein isolate powder (95% protein, w/w) , was obtained from Davisco, USA. Besides ⁇ - lactoglobulin, BiproTM also contains ⁇ -lactalbumin, bovine serum albumin and immunoglobulines .
  • BiproTM solutions were prepared in demineralised water in concentrations of 3, 4, 5 and 6% w/w.
  • the pH was adjusted to pH 2, using HCl.
  • the solutions were heated for 10 hours at 80°C. After cooling, the samples were neutralised with NaOH to pH 7, and cooled further to 3°C, after which CaCl 2 (5 mM) was added to half of the samples. After 3 hours, all samples were assessed visually.
  • the results are given in table 2.
  • a control experiment was carried out in the following way. BiproTM solutions in demineralised water were made (3, 4, 5, 6% w/w) having a pH of 7. The solutions were heated at 80°C for 10 hrs, then cooled to 3°C and CaCl 2 was added to half of the samples. After 3 hours, the samples were assessed visually. The results are shown in Table 2.
  • the objective of this example was to study the effect of addition of seeds to fresh protein material prior to heating at pH 2.
  • the total protein concentrations, the ratios between fresh protein material and seeds (fresh/seeds), and the heating time of both seeds and the mixtures of fresh and seeds were varied.
  • the total protein concentration at which seeds were made was kept constant, in order to have the same seeds in the different experiments.
  • the protein material was BiproTM, a whey protein isolate powder (95% protein, w/w).
  • BiproTM was obtained from Davisco, and is composed of -70% ⁇ -lactoglobuling, ⁇ 18% ⁇ -lactalbumin, ⁇ 6% bovine serum albumin, and -6% immunoglobulins .
  • the protein powder was dissolved in NANOpureTM water and left to stir at room temperature for 3 hours. Next the pH was adjusted to pH 4.75, using 6 M HCl.
  • the protein solution was centrifuged at 12000 rpm for 30 min at room temperature, using a SLA-1500 super lite aluminium rotor in the Sorvall RC-5B refrigerated superspeed centrifuge. At pH 4.75, which is close to the iso- electric point, undissolved protein is precipitated.
  • the pH of the BiproTM solution was set at pH 2, using 6 M HCl.
  • the protein concentration was determined using a UV spectrophotometer and a calibration curve of known protein concentrations at wavelength 278 nm.
  • a BiproTM stock solution of 1.2 % (w/w) at pH 2 was prepared according to the method described above. Different samples were taken and heated for 2, 5, or 10 h at 80°C. After heating the samples were cooled and stored in a refrigerator. Part of each sample was diluted to 0.8 and 0.4% BiproTM. Also the unheated BiproTM solution was diluted to 0.8 and 0.4% BiproTM. These "stock" solutions of unheated (fresh) and heated material (seeds) after different heating times were mixed in different ratios and heated for different times at pH 2 and 80°C.
  • TEM micrographs were made in order to obtain insight in the structures formed upon heating the BiproTM samples for different heating times and to see whether there are differences between samples.
  • the samples (heated at 1.2% BiproTM at pH 2) were diluted to 0.05%.
  • the TEM samples were prepared by negative staining. A drop of the diluted solution was deposited onto a carbon support film on a copper grid. The excess was removed after 15 s using a piece of filter paper. A droplet of 2% PTA (pH 5.5) was added for 15 s, any excess being removed with filter paper. The grid was left to dry to the air.
  • Electron micrographs were made using a Philips CM 12 Transmission Electron Microscope operating at 80 kV. The sample that was heated for 2 h did not show fibrils. In the samples that were heated for either 5 or 10 h long fibrils were visible (see Figure IA) .
  • BiproTM solution is prepared and purified as follows. BiproTM is solubilised in water in a concentration of 10, 12.5 en 15%. These solutions are acidified to pH 4.75 with 6M HCl by adding the HCl solution drop by drop under constant stirring. At pH 4.75 the BiproTM solution turns white with large flakes which sediment slowly. The solution is centrifuged at 10 min, 9000 rpm in a Sorvall superspeed RC2-B centrifuge, GSA rotor (13.200g). The clear supernatant is collected and spray dried at pH 4.75. The pellet is discarded. The fibrils are formed by heating the purified
  • BiproTM solution at pH 2 (acidified with 6M HCl) during 10 hours.
  • the solution is cooled down by gradually (0.5-1 hour) cooling the water bath from 80 to 20°C.
  • the pH is increased by adding NaOH (2M) under stirring.
  • the solution turns white between pH 4 and 5.5 and slowly becomes clear upon further increasing the pH.
  • Fibrils formed of purified BiproTM are called 2-step fibrils and in case non-purified BiproTM is used it is called 1-step fibrils.
  • Foam is obtained by whipping under standard conditions a 3% protein solution for 5 min at speed 3 in a Hobart mixer (model N-50) provided with a standard bowl and wire whisk. The foam is transferred to a round bottom bowl of stainless steel with a diameter of 10 cm, height 5.4 cm, a volume of 270 ml and a weight of 52.1 g.
  • the overrun and stability are measured as follows. For the overrun the round bottom bowl is weighed (A) and filled with foam. A spatula is used to straighten the surface and this bowl is weighed again (B) . For the stability the foam is brought in a weighted powder funnel (D) and the filled funnel (CO) is weighed. The funnel is brought above the cylinder and the cylinder (Wt) and funnel (Et) are weighed after 15, 30, 45 and 60 min.
  • the overrun and stability (drainage) are calculated as follows.
  • Wt weight cylinder after 15, 30, 45 or 60 min drainage
  • C weight funnel and foam after filling
  • D weight empty funnel.
  • BiproTM and 2-step fibrils are shown. The results show that whipping at pH 7 gives a high overrun and a 76% drainage in 60 min. Whipping of the same fibrils at pH 5 gives 50% lower overrun but only 32% drainage in 60 min. As a comparison purified BiproTM is whipped and this gives a low overrun and a high drainage.
  • BiproTM fibrils are formed at 3-6% BiproTM concentration. These solutions are diluted to 3% and whipped. The concentration at which the fibrils are made does hardly effect the overrun, the drainage seems somewhat smaller in case the fibrils are made at higher concentrations (Table 5) .
  • the whipping experiments are performed with 1-step fibrils. Additionally, there is salt added before heat treatment and salt is also present during whipping. In general addition of salt causes the formation of larger structures during heating and a better overrun and foam stability.
  • EXAMPLE 8 Use of the protein additive of the invention as a thickening agent in custard-like cream dessert
  • Modified BiproTM was obtained by freeze-drying a sufficient amount of the neutralized 5% solution as described in Example 3. The powder thus obtained can be used directly in the applications below, or mixed with calcium chloride prior to use in the applications.
  • Yogurt A (reference) was prepared as follows. 117 grams of EsprionTM 300U was dissolved in 1 liter of water. 280 Grams of this solution was mixed with 720 grams of skim milk. The final protein concentration of this solution was 3.5% (w/w). The solution was heated to 65°C and homogenised at this temperature, after which it was pasteurised for 6 minutes at 92°C. The pasteurised milk was cooled to 32°C, and inoculated with a yogurt culture (0.02 % YoflexTM 380 from Chr. Hansen) . Fermentation was continued for approx. 14-16 hours until a pH of 4.2-4.3 was reached.
  • Drinking yogurt was prepared by blending the freshly prepared yogurt with a fruit preparation (25% water, 25% fruit juice, 50% sugar obtainable from Wild, Germany) in a ratio 80% yogurt/20% fruit preparation. Before adding to the yogurt, the fruit preparation was pasteurised at 85°C for 5 minutes and cooled to 20°C. The mixture of yogurt and fruit preparation was subjected to a low-pressure homogenisation at 1-3 MPa. The drinking yogurt was then cooled to ⁇ 10°C , packaged and stored below 10°C.
  • Drinking yogurt was prepared in a comparable way as described for (drinking) yogurt A.
  • the foaming capacity of the composition of the invention was tested in the preparation of meringue.
  • compositions were prepared according to the following table. Composition (%)
  • the BiproTM protein is mixed with the sugar. Then
  • the amount of foam of the control composition is essentially equal to the composition of the invention ( Figure 2A) .
  • the composition of the invention leads to a foam that is more stiff than the control.
  • the control meringue has an overrun of 98 % and a penetration of 15 mm with the light-weight measuring probe (43 g) .
  • the meringue of the invention is more firm and has an overrun of 80 % and 10 mm penetration with the same measuring probe.
  • the thus obtained foam has a volume of
  • BiproTM that was not treated according to the invention. In order to obtain a reasonable amount of foam the solution had to be whipped for 5 min. in the Hobart in speed 3 to achieve an overrun of 700%.
  • Powdered sugar 3 g Powdered sugar 3 g BiproTM 0.5 g Protein of the invention 0.5 g
  • Cappuccino was made by mixing a cappuccino foamer (DP 387 from DMV International, the Netherlands), with sugar and the reference protein BiproTM (ex. A), or the product (spray dried) of the invention (ex. B.). Subsequently 100 ml of boiling water was poured on the powder mix, and the cappuccino foam was assessed after 5 minutes.
  • B 10 mm foam with firmer body as in A; more stable foam compared to A, milky, frothy.
  • the protein according to the invention clearly improves the foaming properties of a cappuccino foamer ( Figure 3) .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Paints Or Removers (AREA)
  • Dairy Products (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Cosmetics (AREA)

Abstract

The invention relates to a method for improving the functional properties of globular proteins, comprising the steps of providing a solution of one or more globular proteins, in which solution the protein(s) is/are at least partially aggregated in fibrils; and performing one or more of the following steps in random order: increasing the pH; increasing the salt concentration; concentrating the solution; and changing the solvent quality of the solution. Preferably, the solution of the one or more globular protein is provided by heating at a low pH or the addition of a denaturing agent. The invention also relates to the protein additive thus obtained, to the use thereof for food and non-food applications and to the food and non-food products containing the protein additive.

Description

METHOD FOR IMPROVING THE FUNCTIONAL PROPERTIES OF A GLOBULAR PROTEIN, PROTEIN THUS PREPARED, USE THEREOF AND PRODUCTS CONTAINING THE PROTEIN
The invention relates to a method for improving the functional properties of a globular protein. The invention further relates to the protein thus prepared, to the use thereof in various products as a protein additive, in particular as a thickening agent, foaming agent, viscosity enhancing agent and/or gelling agent and to the products comprising such additive.
Food and non-food additives are inter alia concerned with improving and maintaining product quality. They are for example used to provide texture, consistency and stability. For this they have functional properties such as foaming properties, gelling properties, emulsifying properties, thickening properties etc.
For food applications, additives can be roughly divided into two groups, polysaccharides and proteins. Examples of the first group having thickening properties are e.g. guar gum, xanthan gum, locust bean gum. Examples of the second group are e.g. milk proteins. Among the milk proteins, whey proteins are widely used as ingredients in food products for their ability to form gels. β-Lactoglobulin is the major protein component of the whey protein from milk. It is a globular protein with a molar mass of 18.3 kDa and a diameter of about 2 nm. When the protein is dissolved in an aqueous solution above a certain critical concentration and heated above the denaturation temperature (about 78 °C) it forms a gel. The globular structure unfolds at least partially and aggregates are formed. The gel is formed by heat treatment if the concentration of the protein is above a critical value (CP) , and an appropriate ionic strength is applied.
Polysaccharides have the advantage that they are effective thickeners in food products, even in low amounts. However, the price of these hydrocolloids is normally high. Moreover, at elevated concentrations they may often give rise to taste defects. When used in dairy products like desserts, they are considered non-natural.
Proteins are normally less effective (on a w/w basis) in thickening compared to hydrocolloids. Thus, even though their price may be considerably lower than for hydrocolloids, the higher dose required abolishes the price advantage.
As explained above, globular proteins form a gel when heated at neutral pH (around 7) . However, the concentration needed to form the gel is relatively high, e.g. more than 5% (w/w) . Moreover, a gel thus obtained is irreversibly formed and is therefore not suitable for use as thickener in a range of products. The gel would have to be dried and/or comminuted thus losing its thickening capacity. On the other hand, if whey proteins are thermally modified at neutral pH and low concentrations to avoid the undesired gel formation, the thickening capacity is very poor or not present at all.
In general there is a desire in the food industry to avoid additives that are non-natural. Proteins are a potential natural source for the preparation of additives but their functional properties are often not comparable to the presently used additives.
There is thus a need for proteins that have good functional properties, in particular thickening, gelling, foaming and emulsifying properties, and that are preferably highly effective at low concentrations.
In the research that led to the present invention it was found for β-lactoglobulin that the structures obtained at low pH confer to the solution containing them a much higher viscosity and have thus a higher gelling capacity than the structures formed by heating β-lactoglobulin at pH 7. Gelling agents of such low pH are however not practically useful. When a solution of β-lactoglobulin is heated at a pH of about 2, denaturation leads to a different type of aggregation than at neutral pH. This low-pH denaturation leads to protein aggregates which are joined by physical forces, whereas denaturation at a pH around 7 or higher will lead to aggregates which are covalently bound through disulfide bonds.
It was found that heating a solution of β- lactoglobulin at a pH around 2 leads to formation of fibrillar protein structures. As stated above, it is generally accepted that these fibrils are constituted by aggregates held together by physical forces. The skilled person would expect that fibrils thus formed would decompose again upon pH increase.
In the research that led to the present invention it was surprisingly found that these fibrils are irreversibly formed when the heating time at or above denaturation temperature is longer than 10 minutes. The same observations were made for whey protein isolates and the teaching of the invention is thus applicable to globular proteins in general and to β-lactoglobulin and whey protein isolates and concentrates in particular.
It was furthermore found that similar fibrillar protein structures can be obtained when a denaturing agent is added to the solution comprising the globular protein. The invention thus relates to a method comprising the steps of: a) providing a solution of one or more globular proteins, in which solution the protein is at least partially aggregated in fibrils; and b) performing one or more of the following steps in random order: i) adjusting the pH of the solution to about neutral; ii) increasing the salt concentration in the solution; ii) concentrating the solution; iii) changing the solvent quality of the solution. In this way a protein additive is obtained having improved functional properties. Method step a) provides the fibrillar structures in the protein solution whereas method step b) triggers the protein such that it is ready to perform its function as a foaming, thickening, gelling or emulsifying agent upon addition thereof to the final product.
Providing a solution of the one or more globular proteins, in which solution the one or more proteins are at least partially aggregated in fibrils, can be achieved in various ways. In a first embodiment the fibril-containing solution of the one or more globular proteins is provided by heating a solution of the protein above room temperature, preferably at a temperature between 50 and 100°C, at a pH between 0.5 and 4, preferably between 0.5 and 3. In an alternative embodiment the fibril-containing solution of the one or more globular proteins is provided by adding a denaturing agent to the solution. The denaturing agent can be a hydrotropic or chaotropic agent and is for example selected from the group consisting of ureum, guanidinium chloride, alcohols, such as methanol, ethanol, propanol, butanol, trifluorethanol . The treatment with the denaturing agent can be performed at a pH between 0.5 and 14, preferably between 3 and 11, more preferably between 5 and 9.
In solutions containing globular proteins that are treated in this way, fibrils are formed having an unexpectedly high gelling and/or thickening and/or foaming and/or emulsifying capacity. The fibrils are irreversibly formed and can be used at any desired pH or ionic strength.
Heating the solution in the first embodiment of step a) is preferably performed during at least 10 minutes, preferably at least 1 hour, more preferably at least 6 hours, most preferably at least 8 hours.
The pH of the treatment of the first embodiment of step a) is preferably below 2.8, preferably below 2.5, more preferably below 2.2. Suitable acids for adjusting the pH to this value are food grade acids, such as hydrochloric acid, phosphoric acid, nitric acid or sulphuric acid.
The total heating time required to obtain the effect may be achieved by batch wise heating, continuous flow heating or a combination of subsequent heating steps, e.g. by means of circulating a solution through a heating system.
Optionally, the solution is cooled before performing one or more of steps i) to iii) .
It is preferred to cool the solution to a temperature between the denaturation temperature and 20°C, preferably between the denaturation temperature and 5°C.
When the pH is increased this is preferably to a value between 3.9 and 9, preferably to about neutral pH. Most food applications have a neutral, near neutral or slightly acidic pH.
Advantageously, the salt concentration is increased to a maximum of 0.2 M, preferably to 0.1 M. The salt used for increasing the salt concentration is preferably the salt of a divalent ion, preferably calcium. It was found that by adding calcium the functional properties are further improved. According to a preferred embodiment step i) is performed prior to step ii) because pH adjustment in dilute systems is easier to carry out.
Changing the solvent quality of the solution can be performed by removing the denaturing agent, for example by dilution or dialysis.
In a further embodiment of the invention the method further comprises addition of already formed fibrils to the solution of globular proteins prior to the heating step. It • was found that by means of this so-called seeding the heating time could be reduced. It was furthermore found that an even lower critical gelling concentration (Cp) could be obtained in samples that had been seeded as compared to samples that were not seeded. Seeds for addition to the solution can be prepared in the same way as the protein of the invention.
In order to obtain a dry product which is more stable upon storage the method further comprises the step of drying the solution to obtain a dry product. It was found that upon reconstituting the protein additive of the invention from the powder obtained after drying the same or similar functional properties were obtained. It is practical when the drying comprises spray drying. The dry product is preferably a powder. Alternatively granulates can be envisaged.
Furthermore it is possible to dilute a gel obtained after concentrating the heated solution according to step b) iii) of the method to a less viscous product by addition of a pH 2 solution. The same applies to a solution treated according to step b) ii) by lowering the salt concentration again.
Advantageously, the globular protein is a protein that is substantially non-denatured and is capable of being thermally denatured at a temperature at or above the denaturation temperature of the protein or chemically denatured.
The method of the present invention can be performed with a wide variety of globular proteins, such as whey proteins, egg albumins, blood globulins, soy proteins, wheat proteins, in particular prolamines, potato proteins or pea proteins. In a preferred embodiment, the globular protein is a whey protein isolate or a whey protein concentrate, preferably a whey protein concentrate enriched in (e.g. > 40%) β-lactoglobulin. In a much preferred embodiment the globular protein is β-lactoglobulin.
In a further embodiment the globular protein is the whey protein isolate powder (95% protein, w/w) that is commercially available under the name Bipro™ and is composed of ~70% β-lactoglobuling, -18% -lactalbumin, -6% bovine serum albumin, and ~6% immunoglobulins . The functional properties of this product after having been subjected to the method of the invention can be further improved by purifying the product prior to heating at low pH. Such purification comprises acidification to pH 4.75, centrifugation and use of the supernatant. This treatment results in loss of about 10% (aggregated) protein, mainly BSA.
The invention further relates to a protein additive for food and non-food applications based on a system of one or more proteins that are aggregated to form fibrils, characterized in that the protein additive has improved functional properties as compared to a similar protein additive based on a system of the same one or more proteins in the same concentration in which the proteins are not aggregated into fibrils. Fibrils in this respect are preferably fibrils consisting of protein and having an aspect ratio of 5 or higher. The aspect ratio is the ratio between length and width or length and height or length and diameter. The length of the fibrils is preferably equal to or above 100A and equal to or below 1 mm, preferably below 100 μm. These fibrils can be made visible by means of a microscope. The above described protein additive can be obtained by the method of the invention or by any other means that leads to the above described structural properties.
The protein additive of the invention can be used as a stabilizer of foams, dispersions and emulsions. Foams are systems of a gas in a liquid. Emulsions are liquids in liquids and dispersions are solids in liquids. Usually these systems cannot exist without the help of a stabilising agent that helps in maintaining the disperse phase uniformly distributed in the continuous phase. The protein additive of the invention was found to be very suitable for this purpose. The protein additive can be used in food stuffs, such as dairy products, for example (aerated) desserts, yogurts, flans, in bakery or confectionary applications, such as frappe, meringue, marshmallows, in cream liqueurs or in beverage foamers, such as cappuccino foamers. When using β- lactoglobulin, whey protein concentrate or whey protein isolate as the globular protein that constitutes the protein additive the product obtained can be an all milk product. Whey protein concentrates normally comprise 25-90% (w/w) whey protein. Whey protein isolates usually comprise > 90% whey protein.
The protein additive of the invention can also be used in meat products, e.g. comminuted meat products (Frankfurter sausages), hamburgers, luncheon meat, pate's, poultry, fish meat products or meat replacers on vegetable basis, to enhance the water-binding and/or texture of the product . Alternative applications of the protein additive of the invention can be found in non-food products such as paints, cosmetics, toothpastes, deodorants etc.
The invention further relates to products comprising the protein additive of the invention, such as food stuffs, in particular dairy products or meat products, but also nonfood products, e.g. paints, cosmetics, toothpastes, deodorants .
According to a further aspect thereof the invention relates to a protein composition comprising one or more particles having texturizing properties, wherein the protein molecules are aggregated into fibrils. Texturizing properties comprise the ability to promote or modify the viscosity or gelling ability of a product containing the composition. Preferably, the fibrils have an aspect ratio, which is defined as the ratio between length and width or length and height or length and diameter, of 5 or higher. The length of the fibrils is preferably equal to or above lOOA and equal to or below 1 mm, preferably below 100 μm. The protein additive of the invention has improved functional properties. Functional properties comprise thickening capacity, gelling capacity, foaming capacity and emulsifying capacity and all have to do with the structure and texture of the product containing the additive. The fact that the functional properties of the additive are improved means that the capacity to induce gelling, foaming, thickening or emulsification in the product containing the protein additive is improved as compared to the capacity to do so of the same protein in the same concentration but which is not subjected to the method of the invention.
The present invention will be further illustrated in the examples that follow and that are not intended to limit the invention. In the Examples reference is made to the following figures.
Figure IA shows a TEM photograph of Bipro™ treated according to the invention after different heating times. Figure IB shows TEM photographs of β-lactoglobulin treated according to the invention after neutralization to different pHs .
Figure 2A shows meringue foam of treated and untreated Bipro™ prior to drying. Figure 2B shows meringue foam of treated and untreated Bipro™ after drying.
Figure 3 shows cappuccino foam prepared with treated and untreated Bipro™.
Figure 4 shows the overrun of a foam prepared with treated and untreated Bipro™.
Figure 5 shows the foam stability in time of a product prepared with treated and untreated Bipro™.
Figure 6 shows the drainage in time of a foam prepared with treated and untreated Bipro™. Figure 7 shows the drainage in time of a foam prepared with treated and untreated Bipro™.
EXAMPLES EXAMPLE 1 Preparation of β-lactoqlobulin gels according to the invention, and determination of critical gelling concentration β-Lactoglobulin (β-lg) was obtained from Sigma (L- 0130) and is a mixture of the genetic variants A and B. The protein was dissolved (3% w/w) in a HCl solution at pH 2. To remove traces of calcium ions from the β-lg, and to obtain a protein solution with the same pH and ionic strength as the solvent, the protein was diluted repeatedly with HCl solvent and filtered through a 3K filter in an Omegacell™ membrane cell (Filtron) at 4°C and a maximum pressure of 3 bar. The procedure was stopped, when the pH and conductivity of the diluted solution and the solvent were the same. The β-lg solution was centrifuged at 22600g for 30 min. To remove any traces of undissolved protein, the supernatant was filtered through a protein filter (FP 030/2, 0.45 mm, Schleicher & Schuell). A UV spectrophotometer was used to determine the β-lg concentration at a wavelength of 278 nm. β-Lactoglobulin (w/w) as prepared above diluted to a concentration of 2% was heated at 80°C for 10 h in a water bath. After cooling, the pH was adjusted to pH 7 or 8 with 0.1 and 1 M NaOH. Various CaCl2 concentrations (0.005, 0.0075, 0.01, 0.05, and 0.1 M) were added very carefully on ice, and the solution was mixed well. After this procedure, the solution was poured into the VOR rheometer (Bohlin concentric cylinder geometry C14) to determine the critical gelling concentration. The sample in the VOR was heated from 3°C to 25°C. After 3 h in rest, a strain sweep was performed (frequency 1 Hz, temperature 25°C, strain 0.000206-0.206).
The procedure was repeated for various protein concentrations. To determine the critical gelling concentration Cp, first the G' (the "elastic modulus" , a characteristic for the elastic component of a system) was determined for various protein concentrations (in the linear region of the curve). A plot was made of (G' ) l/t versus concentration c, for t ranging between 1.7 and 4.5. t is a scaling factor. In the fitting procedure, we make use of the physical fact that extrapolation of (G')1/t to zero should yield the same Cp for all t>0. The scaling assumption has the implication that when t is close to the correct value, the data points will be on a straight line. When t is larger than the correct value, the fit through the points will bend away from the straight line and will lie below it. When t is smaller than the correct value, the fit through the points will also bend away from the straight line but will now lie above it. In that case, the slope of the fit at the intercept with the horizontal axis will be zero. Therefore, in the fitting procedure we use the fact that the curvature of the fit will change if different values for t are chosen, while the intercept Cp will have to remain the same. Cp was determined from fits through the data points that are closest to a straight line in determining an average intercept, Cp. It appeared that the Cp values for the protein system according to the invention were considerably lower than for the reference (not-modified) protein system. (see examples)
The results of this experiment are shown in Table 1.
EXAMPLE 2
Preparation of β-lg gels according to the conventional (neutral pH) gelation method, and determination of the critical gelling concentration β-Lactoglobulin (β-lg) was obtained from Sigma (L- 0130) and is a mixture of the genetic variants A and B. The protein was dissolved (3% w/w) in a HCl solution at pH 2. To remove traces of calcium ions from the β-lg, and to obtain a protein solution with the same pH and ionic strength as the solvent, the protein was diluted repeatedly with HCl solvent and filtered through a 3K filter in an Omegacell™ membrane cell (Filtron) at 4°C and a maximum pressure of 3 bar. The procedure was stopped, when the pH and conductivity of the diluted solution and the solvent were the same.
The β-lg solution was centrifuged at 22600g for 30 min. To remove any traces of undissolved protein, the supernatant was filtered through a protein filter (FP 030/2, 0.45 mm, Schleicher & Schuell). A UV spectrophotometer was used to determine the β-lg concentration at a wavelength of 278 nm. 3% β-lg samples at pH 7 or 8 were heated at 80°C for
30 min. After cooling, 0.01 M CaCl2 was added very carefully on ice, and the solution was mixed well. After this procedure, the solution was poured in the VOR (Bohlin concentric cylinder geometry C14). The sample in the VOR was heated from 3°C to 25°C. After 3 h in rest, a strain sweep was performed (frequency 1 Hz, temperature 25°C, strain 0.000206-0.206). Subsequently the critical gelling concentration of the conventionally formed β-lactoglobulin gel was measured. The results are shown in Table 1.
Table 1
Determination of the Critical gelling concentration (gels prepared according to examples 1 and 2)
Heating conditions Example Final [rtu ] Critical gelling no. : pH CaCl2 concentration (% w/w)
PH 2, 10 hrs, 80°C 1 7.0 0 1.3 pH 2, 10 hrs, 80°C 1 7.0 5 1.1 pH 2, 10 hrs, 80°C 1 7.0 7.5 1.0 pH 2, 10 hrs, 80°C 1 7.0 10 0.1
PH 2, 10 hrs, 80°C 1 7.0 50 0.6
PH 2, 10 hrs, 80°C 1 7.0 100 0.7 pH 2, 10 hrs, 80°C 1 8.0 10 0.4 pH 2, 10 hrs, 80°C 1 8.0 50 0.6 pH 2, 10 hrs, 80°C 1 8.0 100 0.9 pH 7, 0.5 hrs , 80°C 2 7.0 10 No gel formed at 3%
PH 7, 0.5 hrs , 80°C 2 8.0 10 No gel formed at 3%
The results show that β-lactoglobulin modified by the acid pretreatment has a higher gelling ability than β- lactoglobulin which is not acid-modified. EXAMPLE 3
Modification of Bipro™
Bipro™, a whey protein isolate powder (95% protein, w/w) , was obtained from Davisco, USA. Besides β- lactoglobulin, Bipro™ also contains α-lactalbumin, bovine serum albumin and immunoglobulines .
Modification of Bipro™ was carried out as follows: Four Bipro™ solutions were prepared in demineralised water in concentrations of 3, 4, 5 and 6% w/w. The pH was adjusted to pH 2, using HCl. The solutions were heated for 10 hours at 80°C. After cooling, the samples were neutralised with NaOH to pH 7, and cooled further to 3°C, after which CaCl2 (5 mM) was added to half of the samples. After 3 hours, all samples were assessed visually. The results are given in table 2. A control experiment was carried out in the following way. Bipro™ solutions in demineralised water were made (3, 4, 5, 6% w/w) having a pH of 7. The solutions were heated at 80°C for 10 hrs, then cooled to 3°C and CaCl2 was added to half of the samples. After 3 hours, the samples were assessed visually. The results are shown in Table 2.
Table 2
Visual rheological properties of modified and not-modified Bipro™ (from Example 3)
Figure imgf000015_0001
Figure imgf000016_0001
From the table it clearly follows that treatment according to the invention, of a whey protein product comprising different types of protein, also leads to strongly enhanced gelling capacity and a strong increase in viscosity.
EXAMPLE 4
Effect of seeding Introduction
The objective of this example was to study the effect of addition of seeds to fresh protein material prior to heating at pH 2. The total protein concentrations, the ratios between fresh protein material and seeds (fresh/seeds), and the heating time of both seeds and the mixtures of fresh and seeds were varied. The total protein concentration at which seeds were made was kept constant, in order to have the same seeds in the different experiments. The protein material was Bipro™, a whey protein isolate powder (95% protein, w/w).
Ma terials and methods
Bipro™ was obtained from Davisco, and is composed of -70% β-lactoglobuling, ~18% α-lactalbumin, ~6% bovine serum albumin, and -6% immunoglobulins . The protein powder was dissolved in NANOpure™ water and left to stir at room temperature for 3 hours. Next the pH was adjusted to pH 4.75, using 6 M HCl. The protein solution was centrifuged at 12000 rpm for 30 min at room temperature, using a SLA-1500 super lite aluminium rotor in the Sorvall RC-5B refrigerated superspeed centrifuge. At pH 4.75, which is close to the iso- electric point, undissolved protein is precipitated. HPLC analysis shows that about 50% of the BSA present in Bipro™ is being removed in this centrifugation step, indicating that the BSA was aggregated. To remove any traces of undissolved protein that did not end up in the pellet the supernatant was filtered through a protein filter (FD 30/0.45 mm Ca-S from Schleicher & Schuell). The centrifugation step at pH 4.75 is further referred to as "purification", meaning removal of aggregated and undissolved material, and the material is called "purified Bipro™".
After centrifugation and filtration the pH of the Bipro™ solution was set at pH 2, using 6 M HCl. The protein concentration was determined using a UV spectrophotometer and a calibration curve of known protein concentrations at wavelength 278 nm.
A Bipro™ stock solution of 1.2 % (w/w) at pH 2 was prepared according to the method described above. Different samples were taken and heated for 2, 5, or 10 h at 80°C. After heating the samples were cooled and stored in a refrigerator. Part of each sample was diluted to 0.8 and 0.4% Bipro™. Also the unheated Bipro™ solution was diluted to 0.8 and 0.4% Bipro™. These "stock" solutions of unheated (fresh) and heated material (seeds) after different heating times were mixed in different ratios and heated for different times at pH 2 and 80°C.
Cold gelation experiments with seeds made at 1.2% Bipro™ were performed as follows. Seeds that were made by heating Bipro™ from the 1.2% stock solution were used after dilution with NANOpure™ adjusted to pH 2 with 6M Hcl to the required total concentrations. The total Bipro™ concentrations studied for this batch were 0.4%, 0.8%, 1.0%, and 1.2% Bipro™. Unheated and heated material were mixed in different ratios (0% seeds, 10% seeds, 20% seeds, 70% seeds, and 90% seeds) and these mixtures were heated for 10 h, at pH 2 and 80°C. After heating, the samples were cooled and set at pH 7, using 1.0 M and 0.1 M NaOH.
Another set of cold gelation experiments was done, but this time the seeds used were prepared at a Bipro™ concentration of 2.0%. In order to be able to go to higher total protein concentrations when mixing seeds and fresh, and also using the same seeds for those different total protein concentrations, a higher concentration for preparing the seeds was needed. The total Bipro™ concentrations studied for this set were 0.8%, 1.0%, 1.2%, 1.4%, and 1.6% Bipro™. Also here fresh and seeds were mixed in different ratios and heated for 10 h. at pH 2 and 80°C. After heating, the samples were cooled and set at pH 7, using 1.0 M and 0.1 M NaOH. In order to see the effect of addition of seeds of non-dialysed, purified Bipro™, a series of test tubes was filled. The mixtures (at pH 2) were heated for either 2, 5, or 10 hours at 80 °C. After cooling the samples to room temperature and overnight storage the tubes were visually examined. All gelation experiments were performed at 10 mM CaCl2.
The samples that were heated in the presence of seeds and subsequently cooled and set at pH 7 were cooled on ice prior to addition of CaCl2, in order to slow down the reaction rate of cold gel formation upon addition of calcium. A Paar Physica MCR 300 stress controlled rheometer with a concentric cylinder geometry (CC10) was used. The rheometer was cooled to 3°C before the sample was put into the geometry. The rheometer was heated to 25°C. After 3 h of rest at 25°C a strain sweep was performed (frequency 1 Hz, temperature 25°C, strain 0.001- 1) . Resul ts
Mixtures of seeds and fresh Bipro™ of different concentrations (%) (w/w) were heated for 2, 5, or 10 h at pH 2 at 80°C. After cooling of the samples they were visually examined. It was found that upon the addition of seeds, gelation occurs at a lower total protein concentrations than when no seeds are present. Furthermore it was found that for a higher total protein concentration a higher G' is observed. When a higher amount of seeds is present during heating, a higher G' is observed and when the added seeds were heated for a longer time, the resulting G' after mixing with fresh and heating again is higher than for shorter heating time of the seeds. In addition, longer heating of the mixtures of fresh and seeds result in higher G' . When plotting the graphs for different total Bipro™ concentrations for a certain amount of seeds present upon heating, Cp values per seeds-concentration were determined. From the linear regime of the strain sweep curves (i.e. where the G' is independent of the strain), G' was determined. The method to determine Cp and t is described by Van der Linden and Sagis, Langmuir 17, 5821 (2001), which is the same method as in Example 1.
The resulting Cp and t values for the different amount of seeds present during heating of the samples are given in Table 3.
Table 3
Calculated values for Cp and t
Figure imgf000019_0001
Figure imgf000020_0001
From Table 3 it can be concluded that the critical percolation concentration (also known as critical gelling concentration) is decreased due to the presence of seeds. This means that less protein is needed for obtaining the same result.
EXAMPLE 5
Transmission Electron Microscopy Bipro™
TEM micrographs were made in order to obtain insight in the structures formed upon heating the Bipro™ samples for different heating times and to see whether there are differences between samples. The samples (heated at 1.2% Bipro™ at pH 2) were diluted to 0.05%. The TEM samples were prepared by negative staining. A drop of the diluted solution was deposited onto a carbon support film on a copper grid. The excess was removed after 15 s using a piece of filter paper. A droplet of 2% PTA (pH 5.5) was added for 15 s, any excess being removed with filter paper. The grid was left to dry to the air. Electron micrographs were made using a Philips CM 12 Transmission Electron Microscope operating at 80 kV. The sample that was heated for 2 h did not show fibrils. In the samples that were heated for either 5 or 10 h long fibrils were visible (see Figure IA) .
β-lactoglobulin Transmission Electron Microscope (TEM) photographs were made of the samples after heat treatment at pH 2, and of samples that were neutralized at pH 7 and 8 (see Figure IB) . From this it follows that the fibrils do not disintegrate upon neutralisation.
Description of the sample preparation for TEM: The following samples: a) 2 % beta-lactoglobuline, pH 2, 10 hrs 80°C b) as a), but neutralized to pH 7 using 1.0 and 0.1 M NaOH c) as a), but neutralized to pH 8 using 1.0 and 0.1 M NaOH were diluted to 0.04 % beta-lactoglobuline. The TEM samples were prepared by negative staining. A drop of the diluted solution was deposited onto a carbon support film on a copper grid. The excess was removed after 30 seconds using a piece of 'filter paper. A droplet of 2 % uranyl acetate pH 3.8, was added for 15 seconds; any excess was removed again as before. Electron micrographs were made using a Philips CM 12 Transmission Electron Microscope operating at 80 kV.
EXAMPLE 6 Effect of pH, drying and concentration on overrun and stability of foam
Introduction
Various experiments have been performed in which foam properties of the fibrils formed are determined. In this the effect of pH, drying and concentration at which the fibrils are formed on the foam properties is tested.
Ma terial and Methods
A Bipro™ solution is prepared and purified as follows. Bipro™ is solubilised in water in a concentration of 10, 12.5 en 15%. These solutions are acidified to pH 4.75 with 6M HCl by adding the HCl solution drop by drop under constant stirring. At pH 4.75 the Bipro™ solution turns white with large flakes which sediment slowly. The solution is centrifuged at 10 min, 9000 rpm in a Sorvall superspeed RC2-B centrifuge, GSA rotor (13.200g). The clear supernatant is collected and spray dried at pH 4.75. The pellet is discarded. The fibrils are formed by heating the purified
Bipro™ solution at pH 2 (acidified with 6M HCl) during 10 hours. The solution is cooled down by gradually (0.5-1 hour) cooling the water bath from 80 to 20°C. The pH is increased by adding NaOH (2M) under stirring. The solution turns white between pH 4 and 5.5 and slowly becomes clear upon further increasing the pH.
Fibrils formed of purified Bipro™ are called 2-step fibrils and in case non-purified Bipro™ is used it is called 1-step fibrils. Foam is obtained by whipping under standard conditions a 3% protein solution for 5 min at speed 3 in a Hobart mixer (model N-50) provided with a standard bowl and wire whisk. The foam is transferred to a round bottom bowl of stainless steel with a diameter of 10 cm, height 5.4 cm, a volume of 270 ml and a weight of 52.1 g.
The overrun and stability are measured as follows. For the overrun the round bottom bowl is weighed (A) and filled with foam. A spatula is used to straighten the surface and this bowl is weighed again (B) . For the stability the foam is brought in a weighted powder funnel (D) and the filled funnel (CO) is weighed. The funnel is brought above the cylinder and the cylinder (Wt) and funnel (Et) are weighed after 15, 30, 45 and 60 min.
The overrun and stability (drainage) are calculated as follows.
Overrun (%) = ( V * S / ( B - A ) * 100 ) - 100 V = volume round bottom bowl
S = specific weight protein solution-
B = weight bowl and foam
A = weight bowl
Stability (%) = ( ( ( C -D ) - (C -E ) ) / (C -D) ) 100
C = funnel + foam after filling D = weight empty funnel Et = weight funnel after 15, 30 45 or 60 min drainage.
Drainage (%) Wt / (C D) 100
Wt = weight cylinder after 15, 30, 45 or 60 min drainage C = weight funnel and foam after filling D = weight empty funnel.
Resul ts and Discussion Effect of pH In Table 4 the results of the foam tests of native
Bipro™ and 2-step fibrils are shown. The results show that whipping at pH 7 gives a high overrun and a 76% drainage in 60 min. Whipping of the same fibrils at pH 5 gives 50% lower overrun but only 32% drainage in 60 min. As a comparison purified Bipro™ is whipped and this gives a low overrun and a high drainage.
Table 4
Figure imgf000023_0001
Figure imgf000024_0001
Effect of concentration at which the fibrils are formed
2-step Bipro™ fibrils are formed at 3-6% Bipro™ concentration. These solutions are diluted to 3% and whipped. The concentration at which the fibrils are made does hardly effect the overrun, the drainage seems somewhat smaller in case the fibrils are made at higher concentrations (Table 5) .
Table 5
Figure imgf000024_0002
Effect of drying
The whipping experiments are performed with 1-step fibrils. Additionally, there is salt added before heat treatment and salt is also present during whipping. In general addition of salt causes the formation of larger structures during heating and a better overrun and foam stability.
The results in Table 6 show that freeze drying hardly effects the overrun and the draiage. It also shows the poor foam properties of native Bipro™.
Table 6
Figure imgf000025_0001
EXAMPLE 7
Foaming test
75 Grams of a 3% solution of purified Bipro™ and purified Bipro™ treated according to the invention were whipped in a Hobart N 50 mixer for 5 min at speed 3. The overrun of Bipro™ was 1600%, whereas the overrun of Bipro™ fibrils (i.e. Bipro™ treated according to the invention) was 3400%. When non-purified Bipro™ without fibrils was used as a starting product the overrun was only 450%. Figures 4-7 show the results. It follows that Bipro™ fibrils show a very high overrun. The foam drains in time, but drainage is much quicker for untreated Bipro™.
EXAMPLE 8 Use of the protein additive of the invention as a thickening agent in custard-like cream dessert
Modified Bipro™ was obtained by freeze-drying a sufficient amount of the neutralized 5% solution as described in Example 3. The powder thus obtained can be used directly in the applications below, or mixed with calcium chloride prior to use in the applications.
Composition:
A. traditional B. invention
(grams) (grams)
Skim milk 355 355 Cream (40% fat) 65 65 Water 444 444 Protein:
Esprion 300U 10
(DMV International)
Modified Bipro™ 0.8 Saccharose 60 60 Lactose 28 37
Modified starch 38 38
(C*tex 06201 from Cerestar) Carrageenan 0.3 0.3
(CL 360C, Danisco) Flavouring q.s. q.s.
(e.g. vanilla) Colouring q.s. q.s. Esprion™ 300U is a whey protein concentrate having 30% protein (w/w) .
All the ingredients were mixed in the cold milk (approx. 7°C) , and left to hydrate for 20 minutes at a temperature < 10°C. The mixture was heated for 10-20 seconds at 140°C using an UHT pasteuriser (APV, Denmark) fitted with a holding tube, and subsequently cooled to < 10°C, and packaged. Storage was at a temperature below 10°C.
Products obtained are tested by a panel, and a texture measurement was carried out using the Stevens Texture Analyser™ (Stevens Instruments, UK) equipped with a disc probe. The resistance of the probe was measured as the probe penetrates the sample within a determined period of time over a specified distance. The test results showed that, despite the low dosage of modified Bipro™, the texture of Sample B was much better (better mouth feel, higher viscosity) than sample A.
EXAMPLE 9 Use of the protein additive of the invention as a thickening agent in in drinking yogurt
Yogurt A (reference) was prepared as follows. 117 grams of Esprion™ 300U was dissolved in 1 liter of water. 280 Grams of this solution was mixed with 720 grams of skim milk. The final protein concentration of this solution was 3.5% (w/w). The solution was heated to 65°C and homogenised at this temperature, after which it was pasteurised for 6 minutes at 92°C. The pasteurised milk was cooled to 32°C, and inoculated with a yogurt culture (0.02 % Yoflex™ 380 from Chr. Hansen) . Fermentation was continued for approx. 14-16 hours until a pH of 4.2-4.3 was reached. Drinking yogurt was prepared by blending the freshly prepared yogurt with a fruit preparation (25% water, 25% fruit juice, 50% sugar obtainable from Wild, Germany) in a ratio 80% yogurt/20% fruit preparation. Before adding to the yogurt, the fruit preparation was pasteurised at 85°C for 5 minutes and cooled to 20°C. The mixture of yogurt and fruit preparation was subjected to a low-pressure homogenisation at 1-3 MPa. The drinking yogurt was then cooled to < 10°C , packaged and stored below 10°C.
Yogurt B including the protein preparation according to the invention was prepared in a similar way as A but the starting milk was composed of 280 grams of an 0.8% (w/w) solution of modified Bipro™ (from the same source as example 4; protein content = 90% w/w) and 10.9% lactose was mixed with 720 grams of skim milk. The final protein concentration of this solution was 2.7%
Drinking yogurt was prepared in a comparable way as described for (drinking) yogurt A.
Despite the lower protein concentration in drinking yogurt B, the product obtained had a higher viscosity than the reference drinking yogurt A. A test panel evaluation resulted in a preference for the drinking yogurt B, based on a more pleasant mouth feel.
EXAMPLE 10 Use of the protein additive of the invention as a foaming agent in meringue
The foaming capacity of the composition of the invention was tested in the preparation of meringue.
Compositions were prepared according to the following table. Composition (%)
Control Invention
Castor sugar 98.2 98.2 Bipro™ 1.8 Bipro™ fibrils 1.8 Total 100 100
The Bipro™ protein is mixed with the sugar. Then
300 g thereof is added to a grease free mixing bowl (Hobart N 50) . Subsequently, 150 g cold water is added and the composition thus obtained is mixed for 1 min (speed 1) and whipped for 6 min (speed 3) .
After 6 min whipping, the amount of foam of the control composition is essentially equal to the composition of the invention (Figure 2A) . The composition of the invention leads to a foam that is more stiff than the control.
Subsequently the two variants of the foam were made into a meringue by adding 130 g sugar for each 200 g composition. The foam thus obtained is poured in small quantities on grease free paper and dried in the oven for 30 minutes at 125 °C. Figure 2B shows that the addition of a protein additive of the invention leads to a better formed meringue than when untreated Bipro™ is used.
The control meringue has an overrun of 98 % and a penetration of 15 mm with the light-weight measuring probe (43 g) . The meringue of the invention is more firm and has an overrun of 80 % and 10 mm penetration with the same measuring probe.
EXAMPLE 11
Use of the protein additive of the invention as a foaming agent in dessert applications
A solution of 3 % (w/v) of Bipro™ treated according to the invention in water was whipped during 1 min. in a
Hobart mixer, speed 3. The thus obtained foam has a volume of
1100% and a good stability.
To a solution of 3 % (w/v) of the protein of the invention extra calcium (0.13 %) was added as Ca-lactate and treated as above. The stability of the foam is the same as without the addition of calcium.
In a third experiment 10 % sugar is added to the calcium containing solution of the second experiment. The mixture thus obtained is whipped in the same way resulting in an overrun of 900%. The foam is more stable than without the sugar.
The same series of experiments was performed with
Bipro™ that was not treated according to the invention. In order to obtain a reasonable amount of foam the solution had to be whipped for 5 min. in the Hobart in speed 3 to achieve an overrun of 700%.
It thus follows that the treatment of the invention leads to a higher foaming ability. In order to test the use of the treated Bipro™ of the invention as a foamig additive in desserts, a solution of
3 % (w/v) of the protein of the invention and extra calcium
(0.13 %) was mixed with 10 % sugar and 5 % instant starch
(Cerestar 12170 ) and whipped for 3 minutes. Already after 1 minute a foam was obtained but after 3 minutes the foam was firm and short with an overrun of 400 %. Addition of 1% citric acid leads to an even better foam formation of about 600 %. The foaming capacity as compared to untreated
Bipro™ is spectacular. EXAMPLE 12
Cappuccino foamer Recipe :
A: DP 387 5 g B: DP 387 5 g
Powdered sugar 3 g Powdered sugar 3 g Bipro™ 0.5 g Protein of the invention 0.5 g
Cappuccino was made by mixing a cappuccino foamer (DP 387 from DMV International, the Netherlands), with sugar and the reference protein Bipro™ (ex. A), or the product (spray dried) of the invention (ex. B.). Subsequently 100 ml of boiling water was poured on the powder mix, and the cappuccino foam was assessed after 5 minutes.
Foam height Foam appearance, taste
A : 7 mm good foam, fine structure
B : 10 mm foam with firmer body as in A; more stable foam compared to A, milky, frothy.
The protein according to the invention clearly improves the foaming properties of a cappuccino foamer (Figure 3) .

Claims

1. Method for improving the functional properties of globular proteins, comprising the steps of: a) providing a solution of one or more globular proteins, in which solution the protein is at least partially aggregated in fibrils; and b) performing one or more of the following steps in random order: i) adjusting the pH of the solution to about neutral; ii) increasing the salt concentration in the solution; iii) concentrating the solution; iv) changing the solvent quality of the solution.
2. Method as claimed in claim 1, wherein the fibril-containing solution of the one or more globular proteins is provided by heating a solution of the one or more proteins above room temperature, preferably at a temperature between 50 and 100°C, at a pH between 0.5 and 4, preferably between 0.5 and 3.
3. Method as claimed in claim 2, wherein the solution is heated during a period of at least 10 minutes, preferably at least 1 hour, more preferably at least 6 hours, even more preferably at least 8 hours.
4. Method as claimed in any one of the claims 2 and 3, wherein the solution is cooled before performing one or more of steps i) to iv) .
5. Method as claimed in claim 4, wherein the solution is cooled to a temperature between denaturation temperature and 20°C, preferably between denaturation temperature and 5°C.
6. Method as claimed in any one of the claims 2-5, wherein the heating is performed at a pH below 2.8, preferably below 2.5, more preferably below 2.2.
7. Method as claimed in claim 1, wherein the fibril-containing solution of the one or more globular proteins is provided by adding a denaturing agent to the solution.
8. Method as claimed in claim 7, wherein the denaturing agent is a hydrotropic or chaotropic agent.
9. Method as claimed in claim 7, wherein the denaturing agent is selected from the group consisting of ureum, guanidinium chloride, alcohols, such as methanol, ethanol, propanol, butanol, trifluorethanol .
10. Method as claimed in any one of the claims 3-5, wherein the solution has a pH of 0.5-14.
11. Method as claimed in any one of the claims 2- 10, wherein the globular protein is a protein that is substantially non-denatured and is capable of being thermally denatured at a temperature at or above the denaturation temperature of the protein or capable of being chemically denatured.
12. Method as claimed in any one of the claims 2- 11, further comprising the step of adding already formed fibrils to the solution prior to production of the fibril- containing solution.
13. Method as claimed in claim 12, wherein the already formed fibrils are obtainable by the method as claimed in any one of the claims 2-11.
14. Method as claimed in claim 12 or 13, wherein the amount of already formed fibrils based on the total amount of protein is more than 0 and less than 90%, preferably between 10 and 80%, more preferably between 20 and 70%, even more preferably between 30 and 60%.
15. Method as claimed in any one of the claims 1- 14, wherein the pH is increased to a value between 3.9 and 9, preferably to about neutral pH.
16. Method as claimed in any one of the claims 1- 14, wherein the salt concentration is increased to a maximum of 0.2M, preferably to 0.1M.
17. Method as claimed in claim 16, wherein the salt used for increasing the salt concentration is the salt of a divalent ion, preferably calcium.
18. Method as claimed in any one of the claims 1- 17, wherein step i) is performed prior to step ii).
19. Method as claimed in any one of the claims 1- 18, wherein the solvent quality of the solution is changed by removing the denaturing agent.
20. Method as claimed in any one of the claims 1- 19, further comprising the step of drying the solution to obtain a dry product.
21. Method as claimed in claim 20, wherein the drying comprises spray drying.
22. Method as claimed in any one of claims 20-21, wherein the dry product is a powder.
23. Method as claimed in claim 1-22, wherein the globular protein is selected from the group consisting of whey proteins, egg albumins, blood globulins, soy proteins, wheat proteins, in particular prolamines, potato proteins, pea proteins .
24. Method as claimed in claim 23, wherein the globular protein is a whey protein isolate, a whey protein concentrate, and preferably a whey protein concentrate enriched in β-lactoglobulin.
25. Method as claimed in claim 24, wherein the globular protein is the whey protein isolate Bipro™.
26. Method as claimed in any one of the claims 24 and 25, wherein the globular protein is β-lactoglobulin.
27. Protein additive based on a system of one or more proteins that are at least partially aggregated in fibrils, characterized in that the protein additive has improved functional properties as compared to a similar protein additive based on a system of the same one or more proteins in the same concentration in which the proteins are not aggregated in fibrils.
28. Protein additive as claimed in claim 27, wherein the functional properties are one or more of the following: foaming properties, thickening properties, gelling properties and emulsifying properties.
29. Protein additive obtainable by the method as claimed in any one of the claims 1-26.
30. Protein additive as claimed in claim 27 or 28 obtainable by the method as claimed in any one of the claims 1-26.
31. Protein additive as claimed in claim 27 or 28 in dry form obtainable by the method as claimed in any one of the claims 20-26.
32. Protein additive as claimed in any one of the claims 27-31 for use as a stabilizer of foams, dispersions and emulsions .
33. Protein additive as claimed in any one of the claims 27-31 for use in dairy products.
34. Protein additive as claimed in any one of the claims 27-31 for use in meat products.
35. Protein additive as claimed in any one of the claims 27-31 for use in paints.
36. Protein additive as claimed in any one of the claims 27-31 for use in toothpastes, cosmetics, deodorants.
37. Dairy product comprising the protein additive as claimed in any one of the claims 27-31.
38. Meat product comprising the protein additive as claimed in any one of the claims 27-31.
39. Paint comprising the protein additive as claimed in any one of the claims 27-31.
40. Toothpaste comprising the protein additive as claimed in any one of the claims 27-31.
41. Cosmetic comprising the protein additive as claimed in any one of the claims 27-31.
42. Deodorant comprising the protein additive as claimed in any one of the claims 27-31.
43. Protein composition comprising one or more particles having texturizing properties, wherein the protein molecules are aggregated into fibrils.
44. Protein composition as claimed in claim 43, wherein the texturizing properties comprise the ability to promote or modify the viscosity or gelling ability of a product containing the composition.
45. Protein composition as claimed in any one of the claims 43 and 44, wherein the fibrils have an aspect ratio, which is defined as the ratio between length and width or length and height or length and diameter, of 5 or higher.
46. Protein composition as claimed in any one of the claims 43-45, wherein the length of the fibrils is preferably equal to or above lOOA and equal to or below 1 mm, preferably below 100 μm.
PCT/EP2003/013678 2002-11-29 2003-11-28 Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein Ceased WO2004049819A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2004556286A JP2006508160A (en) 2002-11-29 2003-11-28 Method for improving the functional properties of globular proteins, proteins thus prepared, uses of the proteins and products containing the proteins
AU2003293761A AU2003293761B2 (en) 2002-11-29 2003-11-28 Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein
US10/536,713 US20060204454A1 (en) 2002-11-29 2003-11-28 Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein
NZ540406A NZ540406A (en) 2002-11-29 2003-11-28 Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein
EP03789127A EP1565067A2 (en) 2002-11-29 2003-11-28 Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02080019 2002-11-29
EP02080019.9 2002-11-29

Publications (2)

Publication Number Publication Date
WO2004049819A2 true WO2004049819A2 (en) 2004-06-17
WO2004049819A3 WO2004049819A3 (en) 2004-08-19

Family

ID=32405736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013678 Ceased WO2004049819A2 (en) 2002-11-29 2003-11-28 Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein

Country Status (6)

Country Link
US (1) US20060204454A1 (en)
EP (1) EP1565067A2 (en)
JP (1) JP2006508160A (en)
AU (1) AU2003293761B2 (en)
NZ (1) NZ540406A (en)
WO (1) WO2004049819A2 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1645192A1 (en) * 2004-10-07 2006-04-12 Wageningen Centre for Food Sciences Process of preparing a water-continuous filled gel composition
EP1839488A1 (en) * 2006-03-27 2007-10-03 Campina Nederland Holding B.V. Egg-free cake and a method for preparation thereof
WO2008025698A1 (en) 2006-08-29 2008-03-06 Henkel Ag & Co. Kgaa Antiperspirant and deodorant compositions with improved care effect
WO2008069649A1 (en) * 2006-11-10 2008-06-12 Coöperatie Avebe U.A. Protein gel formation
WO2009082229A2 (en) 2007-12-21 2009-07-02 Friesland Brands B.V. Pre-fibril composition and fibrils from proteinaceous materials
GB2460283A (en) * 2008-03-13 2009-11-25 Academia Sinica Method of changing a globular protein structure into a fibrillar protein structure.
EP2123177A1 (en) 2008-05-15 2009-11-25 Friesland Brands B.V. Pre-fibril composition and fibrils from proteinaceous materials
EP2347658A1 (en) * 2010-01-20 2011-07-27 Nestec S.A. Oil gel
RU2432089C2 (en) * 2005-12-21 2011-10-27 Юнилевер Н.В. Food product and its production method
EP2394515A1 (en) * 2005-09-16 2011-12-14 Meiji Dairies Corporation Method of Improving the Texture of Fermented Milk
US8268974B2 (en) 2003-05-29 2012-09-18 Academia Sinica Process to produce fibrillar proteins
WO2012130654A1 (en) 2011-03-29 2012-10-04 Nestec S.A. Frozen confections with improved heat shock stability
WO2012130653A1 (en) 2011-03-29 2012-10-04 Nestec S.A. Aerated food products comprising a protein-based reversible gel
US8357652B2 (en) 2009-11-20 2013-01-22 Academia Sinica Anti-tumor fibrillar human serum albumin methods and compositions
EP2604126A1 (en) 2011-12-13 2013-06-19 Nestec S.A. Aerated food products with improved foam stability
WO2013135778A1 (en) * 2012-03-13 2013-09-19 Danone Gmbh Process for making sweetened fermented dairy products comprising erythritol
CN103491791A (en) * 2011-04-28 2014-01-01 株式会社明治 Dairy product in which whey is used, and method for manufacturing same
WO2014018937A1 (en) * 2012-07-26 2014-01-30 Solae, Llc Foaming agent for use in food compositions
WO2014102181A1 (en) 2012-12-28 2014-07-03 Nestec S.A. Stabilizing system for foam
US9102749B2 (en) 2006-11-10 2015-08-11 Cooperatie Avebe U.A. Protein gel formation
CN106798345A (en) * 2015-11-26 2017-06-06 内蒙古伊利实业集团股份有限公司 Has beta lactoglobulin product of transparent strong gelation and preparation method and application
CN107287698A (en) * 2017-06-20 2017-10-24 中国科学技术大学 A kind of preparation method of carbon nano-fiber aeroge
WO2020002435A1 (en) 2018-06-27 2020-01-02 Arla Foods Amba Acidic beta-lactoglobulin beverage preparation
WO2020001765A1 (en) * 2018-06-27 2020-01-02 Arla Foods Amba Acidic beta-lactoglobulin beverage preparation
WO2020173660A1 (en) * 2019-02-26 2020-09-03 Unilever N.V. Edible composition comprising a structured aqueous phase
US11337440B2 (en) 2012-09-21 2022-05-24 Roquette Freres Assembly of at least one vegetable protein and at least one dairy protein

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104782760A (en) * 2009-01-27 2015-07-22 阿拉食品公司 Long shelf life milk or milk-related products
BR112013018110B1 (en) * 2011-01-17 2021-06-22 Unilever Ip Holdings B.V. SEMI-SOLID FOOD CONCENTRATE, IN THE FORM OF A GEL OR A PASTE, PROCESS FOR THE PREPARATION OF THIS SEMI-SOLID FOOD CONCENTRATE AND USE OF THE CONCENTRATE IN SOUPS, SAUCES OR MEAT BROWS
CN113575968B (en) * 2021-07-01 2023-11-21 合肥工业大学 Ultrasonic-assisted glycosylation modified egg transferrin method
CN113995117B (en) * 2021-11-11 2022-05-17 东北农业大学 Protein-based foaming agent and preparation method and application thereof
CN118077762A (en) * 2022-11-25 2024-05-28 内蒙古伊利实业集团股份有限公司 Low-fat/reduced-fat dairy products and methods for preparing the same
CN118077746A (en) * 2024-03-25 2024-05-28 湖州市农产品质量安全中心(湖州市农畜水产品检测中心) A protein fiber antifreeze water-retaining agent with antioxidant properties and its application in frozen minced meat
WO2026028200A1 (en) * 2024-07-29 2026-02-05 Imagindairy Ltd rBLG COMPOSITIONS AND USES THEREOF

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897570A (en) * 1968-09-17 1975-07-29 Kikkoman Shoyn Co Ltd Preparation of an acidic beverage
US3627536A (en) * 1968-11-04 1971-12-14 Gen Foods Corp Method of producing proteinaceous fibers
US3870805A (en) * 1970-11-04 1975-03-11 Staley Mfg Co A E Process for preparing texturized protein compositions and the resulting product
US3993794A (en) * 1976-01-15 1976-11-23 The United States Of America As Represented By The Secretary Of Agriculture Method for texturizing proteins
JPS5362861A (en) * 1976-11-12 1978-06-05 Kuraray Co Production of high protein fibrous food
DD142144A1 (en) * 1979-03-02 1980-06-11 Siegfried Kummer METHOD FOR THE PRODUCTION OF FIBRILLAERES AND LAMELLAR PROTEIN STRUCTURES
IE52725B1 (en) * 1981-04-13 1988-02-03 Kuraray Co Method for production of formed food product of microfibrillar milk protein
JPS603814B2 (en) * 1981-10-02 1985-01-30 協和醗酵工業株式会社 Modified whey protein manufacturing method
DE3885459T2 (en) * 1987-05-14 1994-03-24 Commw Scient Ind Res Org Whey protein fractions.
US5437885A (en) * 1991-03-15 1995-08-01 Texas A&M University Method of making a non-porous vegetable protein fiber product
GB9108604D0 (en) * 1991-04-22 1991-06-05 Nadreph Ltd Gel products and a process for making them
JPH06508751A (en) * 1991-07-05 1994-10-06 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション Gelled food containing fine particle suspension
DE69220374T2 (en) * 1992-12-23 1998-01-15 Campina Melkunie Bv Process for the production of alpha-lactalbumin and beta-lactoglobulin from a whey protein product
JP2001507939A (en) * 1997-01-14 2001-06-19 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム Organizing agent
US6355295B1 (en) * 2000-02-29 2002-03-12 Protein Technologies International, Inc. Soy functional food ingredient
JP5058427B2 (en) * 2000-09-29 2012-10-24 不二製油株式会社 Production method of soy protein
GB0030926D0 (en) * 2000-12-19 2001-01-31 Univ Heriot Watt Fat replacement product and process for its manufacture
FR2821244B1 (en) * 2001-02-27 2004-12-31 Rhodia Chimie Sa COMPOSITION CONTAINING A MIXTURE OF POLYSACCHARIDES AND GLOBULAR PROTEIN (S), PREPARATION METHOD THEREOF AND USES THEREOF

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268974B2 (en) 2003-05-29 2012-09-18 Academia Sinica Process to produce fibrillar proteins
EP1645192A1 (en) * 2004-10-07 2006-04-12 Wageningen Centre for Food Sciences Process of preparing a water-continuous filled gel composition
EP2394515A1 (en) * 2005-09-16 2011-12-14 Meiji Dairies Corporation Method of Improving the Texture of Fermented Milk
RU2432089C2 (en) * 2005-12-21 2011-10-27 Юнилевер Н.В. Food product and its production method
EP1839488A1 (en) * 2006-03-27 2007-10-03 Campina Nederland Holding B.V. Egg-free cake and a method for preparation thereof
WO2008025698A1 (en) 2006-08-29 2008-03-06 Henkel Ag & Co. Kgaa Antiperspirant and deodorant compositions with improved care effect
US9968118B2 (en) 2006-11-10 2018-05-15 Cooperatie Avebe U.A. Protein gel formation
US9102749B2 (en) 2006-11-10 2015-08-11 Cooperatie Avebe U.A. Protein gel formation
WO2008069649A1 (en) * 2006-11-10 2008-06-12 Coöperatie Avebe U.A. Protein gel formation
WO2009082229A3 (en) * 2007-12-21 2009-08-27 Friesland Brands B.V. Pre-fibril composition and fibrils from proteinaceous materials
WO2009082229A2 (en) 2007-12-21 2009-07-02 Friesland Brands B.V. Pre-fibril composition and fibrils from proteinaceous materials
GB2460283A (en) * 2008-03-13 2009-11-25 Academia Sinica Method of changing a globular protein structure into a fibrillar protein structure.
GB2460283B (en) * 2008-03-13 2010-04-21 Academia Sinica Method of producing fibrillar proteins
EP2123177A1 (en) 2008-05-15 2009-11-25 Friesland Brands B.V. Pre-fibril composition and fibrils from proteinaceous materials
US8357652B2 (en) 2009-11-20 2013-01-22 Academia Sinica Anti-tumor fibrillar human serum albumin methods and compositions
US9226951B2 (en) 2009-11-20 2016-01-05 Academia Sinica Anti-tumor fibrillar human serum albumin methods and compositions
WO2011089171A1 (en) * 2010-01-20 2011-07-28 Nestec S.A. Oil gel
US20120289610A1 (en) * 2010-01-20 2012-11-15 Nestec S.A. Oil gel
US8796342B2 (en) 2010-01-20 2014-08-05 Nestec S.A. Oil gel
EP2347658A1 (en) * 2010-01-20 2011-07-27 Nestec S.A. Oil gel
WO2012130654A1 (en) 2011-03-29 2012-10-04 Nestec S.A. Frozen confections with improved heat shock stability
WO2012130653A1 (en) 2011-03-29 2012-10-04 Nestec S.A. Aerated food products comprising a protein-based reversible gel
US20140370173A1 (en) * 2011-03-29 2014-12-18 Nestec S.A. Frozen confections with improved heat shock stability
CN103491791A (en) * 2011-04-28 2014-01-01 株式会社明治 Dairy product in which whey is used, and method for manufacturing same
RU2619897C2 (en) * 2011-12-13 2017-05-19 Нестек С.А. Aerated food products with improved foam stability
WO2013087354A1 (en) 2011-12-13 2013-06-20 Nestec S.A. Aerated food products with improved foam stability
EP2604126A1 (en) 2011-12-13 2013-06-19 Nestec S.A. Aerated food products with improved foam stability
WO2013135778A1 (en) * 2012-03-13 2013-09-19 Danone Gmbh Process for making sweetened fermented dairy products comprising erythritol
WO2014018937A1 (en) * 2012-07-26 2014-01-30 Solae, Llc Foaming agent for use in food compositions
US11337440B2 (en) 2012-09-21 2022-05-24 Roquette Freres Assembly of at least one vegetable protein and at least one dairy protein
WO2014102181A1 (en) 2012-12-28 2014-07-03 Nestec S.A. Stabilizing system for foam
CN106798345A (en) * 2015-11-26 2017-06-06 内蒙古伊利实业集团股份有限公司 Has beta lactoglobulin product of transparent strong gelation and preparation method and application
CN107287698A (en) * 2017-06-20 2017-10-24 中国科学技术大学 A kind of preparation method of carbon nano-fiber aeroge
CN107287698B (en) * 2017-06-20 2019-10-25 中国科学技术大学 A kind of preparation method of carbon nanofiber airgel
CN112752516A (en) * 2018-06-27 2021-05-04 阿尔拉食品公司 Acidic beta-lactoglobulin beverage product
CN117882811A (en) * 2018-06-27 2024-04-16 阿尔拉食品公司 Acidic β-lactoglobulin beverage products
WO2020002454A1 (en) 2018-06-27 2020-01-02 Arla Foods Amba Instant beverage powder based on blg
WO2020001765A1 (en) * 2018-06-27 2020-01-02 Arla Foods Amba Acidic beta-lactoglobulin beverage preparation
EP4751574A1 (en) * 2018-06-27 2026-06-03 Arla Foods amba Process for producing beta-lactoglobulin isolates and related methods and uses
CN112702925A (en) * 2018-06-27 2021-04-23 阿尔拉食品公司 Instant beverage powder based on BLG
CN112752509A (en) * 2018-06-27 2021-05-04 阿尔拉食品公司 Process for preparing beta-lactoglobulin isolates and related methods and uses
WO2020002426A1 (en) * 2018-06-27 2020-01-02 Arla Foods Amba Process for producing beta-lactoglobulin isolates and related methods and uses
EP4643653A3 (en) * 2018-06-27 2026-02-25 Arla Foods amba Acidic beta-lactoglobulin beverage preparation
WO2020002435A1 (en) 2018-06-27 2020-01-02 Arla Foods Amba Acidic beta-lactoglobulin beverage preparation
CN112752516B (en) * 2018-06-27 2024-01-16 阿尔拉食品公司 Acidic beta-lactoglobulin beverage products
WO2020002450A1 (en) 2018-06-27 2020-01-02 Arla Foods Amba Ph neutral beta-lactoglobulin beverage preparation
EP4696142A1 (en) 2018-06-27 2026-02-18 Arla Foods amba Ph neutral beta-lactoglobulin beverage preparation
US12133543B2 (en) 2018-06-27 2024-11-05 Arla Foods Amba Acidic beta-lactoglobulin beverage preparation
AU2019295120B2 (en) * 2018-06-27 2024-12-19 Arla Foods Amba Acidic beta-lactoglobulin beverage preparation
AU2018429997B2 (en) * 2018-06-27 2025-02-13 Arla Foods Amba Acidic beta-lactoglobulin beverage preparation
CN112752509B (en) * 2018-06-27 2025-02-28 阿尔拉食品公司 Process for preparing beta-lactoglobulin isolate and related methods and uses
EP3813548B1 (en) 2018-06-27 2025-09-17 Arla Foods amba Acidic beta-lactoglobulin beverage preparation
EP3813549B1 (en) 2018-06-27 2025-09-24 Arla Foods amba Ph neutral beta-lactoglobulin beverage preparation
US12453359B2 (en) 2018-06-27 2025-10-28 Arla Foods Amba PH neutral beta-lactoglobulin beverage preparation
EP4643653A2 (en) 2018-06-27 2025-11-05 Arla Foods amba Acidic beta-lactoglobulin beverage preparation
CN113490424B (en) * 2019-02-26 2024-04-26 联合利华知识产权控股有限公司 Edible compositions comprising a structured aqueous phase
CN113490424A (en) * 2019-02-26 2021-10-08 联合利华知识产权控股有限公司 Edible composition comprising a structured aqueous phase
WO2020173660A1 (en) * 2019-02-26 2020-09-03 Unilever N.V. Edible composition comprising a structured aqueous phase

Also Published As

Publication number Publication date
WO2004049819A3 (en) 2004-08-19
NZ540406A (en) 2008-04-30
JP2006508160A (en) 2006-03-09
US20060204454A1 (en) 2006-09-14
EP1565067A2 (en) 2005-08-24
AU2003293761B2 (en) 2009-12-03
AU2003293761A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
AU2003293761B2 (en) Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein
AU2007289444B2 (en) Calcium depleted milk protein concentrates for stabilising foods
EP1839495B1 (en) Protein-enriched frozen dessert
CA1334920C (en) Use of parenchymal cell cellulose to improve comestibles
AU2008241634A1 (en) Dairy product and process
CN1206334A (en) Fortification of foods with calcium complexes
CA2624115A1 (en) Stabilizers and compositions and products comprising same
JP3251858B2 (en) Acidic food and drink, acidic cream and powder for acidic food and drink
Han et al. Fabrication and characterization of non-fat whipped cream analogue: Effects of type and concentration of polysaccharide
WO1993019613A1 (en) Gelling system as a fat substitute
US8647695B2 (en) Aerated food products
EP2670256A1 (en) Aerated food products
JP4078805B2 (en) Carboxylic acid and amino acid or amino acid condensate reaction product and process for producing the same
WO1998031240A1 (en) Texturing agent
KR100319473B1 (en) A method for preparation of ice cream containing silk amino aqueous solution
US20210145022A1 (en) Protein product and methods from acid treated meat emulsion
Imeson et al. Microcrystalline cellulose
Golding Utilizing dairy protein functionality in food microstructure design
Tipvarakarnkoon Material science properties of coconut milk, cheese and emulsion
CN116456839A (en) Food ingredients
CN121867318A (en) Pickering double emulsion-based high-melting-resistance low-fat ice cream and preparation method thereof
Ji New food ingredient derived from casein/kappa-carrageenan interaction
JP2023546051A (en) food ingredients
Haug et al. Department of Biotechnology/Norwegian Biopolymer Laboratory (NOBIPOL), Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
WO2018236740A1 (en) Protein product and methods from alkali treated meat emulsion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003789127

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003293761

Country of ref document: AU

Ref document number: 540406

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004556286

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003789127

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10536713

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10536713

Country of ref document: US